ProCE Banner Activity

CE

Applying Evidence-Based Strategies to Improve Outcomes in HER2-Negative Early Breast Cancer

Video

On-demand webcast of expert faculty presentation and case discussion on the current evidence in HER2-negative early breast cancer and how to apply it in your clinical practice to improve patient outcomes.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 21, 2024

Expiration: May 20, 2025

Share

Faculty

Allison Butts

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Jordan Hill

Jordan Hill, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Provided by

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This program is intended for oncology/hematology pharmacists and other clinical practice stakeholders involved in the care of patients with EBC.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging published data and consensus-based guidelines to determine the appropriate use of biomarkers and genomic classifiers for assessing the risk of recurrence in patients with EBC

  • Develop personalized neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for patients with HR+/HER2- EBC

  • Select appropriate strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes

  • Identify patients who meet the eligibility criteria for ongoing clinical trials investigating novel therapies for HR+/HER2- EBC

Disclosure

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Allison Butts, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
Pharmacist Manager, Oncology
Program Director, PGY2 Hematology/Oncology Pharmacy Residency
UK Healthcare
Lexington, Kentucky

Allison Butts, PharmD, BCOP, has no relevant financial relationships to disclose.

Jordan Hill, PharmD, BCOP

Clinical Pharmacy Specialist, Breast Oncology
West Virginia University Cancer Institute
Morgantown, West Virginia

Jordan Hill, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 21, 2024, through May 20, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Pharmacist

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-24-007-H01-P has been assigned to this home study application-based activity. This activity is approved for 1 contact hour (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.